IZOZF - Izotropic's IzoView is Weeks Away from Final Engineering & Showcasing to Investment and Scientific Communities

(TheNewswire)

VANCOUVER, BC – TheNewswire - October, 252022 – Izotropic Corporation (“ Izotropic ” orthe “ Company ”) (CSE: IZO ) (OTC: IZOZF )(FSE: 1R3 ), a medical device company commercializing IzoView, adedicated breast CT (computed tomography) imaging platform, for themore accurate detection and diagnosis of breast cancers, announcesthat the engineering and construction of IzoView is weeks away fromcompletion and subsequent unveiling to existing shareholders, and theinvestment, medical and scientific communities.

Full assembly of IzoView is approximately four weeksfrom completion, and the imaging subsystem is currently operationaland producing static images with phantoms. Phantoms are stand-inobjects for human tissue that are used to confirm the device isoperating correctly. The final assembly of IzoView will be completedupon receipt of exterior parts that comprise the tabletop, footbox,and headbox, including the housing for the attached computerworkstation.

Investors can expect news releases on the followingmilestones and corporate catalysts through to the end of 2022:

• Announcement of IzoView’s full-motion, 360-degree 3Dimage capture of phantom images.

• Unveiling of IzoView with photographs andvideo.

• Further advancements of machine learning imagereconstruction algorithms in partnership with Johns Hopkins University School of Medicine .

• Milestone plans with projected timelines through theclinical study to the sale of the first IzoView device.

• Overview of pricing and financial models.

• New corporate materials, social media, and marketingplans.

“I want to thank shareholders for being exceedinglypatient with the various delays and my conservative nature in respectto disclosure. With the development stage coming to completion, filingof important IP and the forthcoming presentation of our device, theCompany will be communicating with greater frequency as we move to thenext stage,” said Dr. John McGraw, CEO.

The History of IzoView BreastCT:

Four successive breast CT imaging systems have beenbuilt at UC Davis Medical Centre in California by Company Director andPrincipal Founder of breast CT, Dr. John M.Boone. Each of these systems had better clinical utility and imageperformance than its predecessor. The latest system has incorporatedlessons learned from previous models, and the incorporation ofstate-of-the-art subcomponents have improved clinical utility withexceptional high-resolution CT images of the breast. Izotropic holdsthe rights to this breast CT technology under its exclusive globalLicense Agreement with The Regents of the University ofCalifornia.

The Company’s original strategy was to closely mirrorthe 4th generation Breast CT device that has been under clinicalinvestigation and clinical trials at UC Davis Medical Center andimaged close to 600 patients to date. The intention was for theCompany to mirror the 4 th generation breast CT unit with minorupgrades for its FDA study and finalize user and patient handlingrequirements afterwards. As Covid-19 set in, the Company began tofactor the evolving dynamics, the impacts on supply chains, and theassociated challenges of running a clinical study during a pandemic.At the same time, next-generation primary components became available,and the Company, therefore, decided to adjust the business plan to itsbenefit. As a result, now going into the initial clinical study,comparing IzoView with diagnostic mammography, Izotropic expects todeliver a better-performing system and have a subsequent broaderproduct offering and a more competitively priced Breast CTsystem.

More than U.S. $25M has been invested across allaspects of the breast CT system, with the majority of this capital onR&D and clinical studies at UC Davis Medical Center, fundedprimarily by the National Institutes of Health in the U.S. Over thepast 2 years Izotropic has made specific investments related toengineering capabilities, onboarding personnel, and investigating andfinalizing the IzoView platform strategy. The Company has alsoadvanced its technical planning and documentation, sourced, andpurchased critical components, established redundant manufacturingsources, and implemented a quality management system, which is allnecessary to make IzoView a high-performing device for massuse.

ON BEHALF OF THE BOARD

Dr. John McGraw

Investor Relations Contact:

James Berard

Email: info@izocorp.com

Toll Free: 1-833-IZOCORP ext.1

Media Inquiries Contact:

Jaclyn Thast

Email: jaclyn@izocorp.com

Toll Free: 1-833-IZOCORP ext.3

About Izotropic Corporation

Izotropic Corporation is the only publicly tradedcompany commercializing a dedicated breast CT imaging platform,IzoView, for the more accurate detection and diagnosis of breastcancers. To expedite patient and provider access to IzoView,Izotropic's initial clinical study intends to demonstrate superiorperformance of diagnostic breast CT imaging over diagnosticmammography procedures. In follow-on clinical studies, Izotropicintends to validate platform applications, including breast screeningin radiology, treatment planning and monitoring in surgical oncology,and breast reconstruction and implant monitoring in plastic andreconstructive surgery.

More information about Izotropic Corporation can befound on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com.

Forward-Looking Statements

This document may contain statements that are"Forward-Looking Statements," which are based upon thecurrent estimates, assumptions, projections, and expectations of theCompany's management, business, and its knowledge of the relevantmarket and economic environment in which it operates. The Company hastried, where possible,

to identify such information and statements by usingwords such as "anticipate," "believe,""envision," "estimate," "expect,""intend," "may," "plan,""predict," "project," "target,""potential," "will," "would,""could," "should," "continue,""contemplate" and other similar expressions and derivationsthereof in connection with any discussion of

future events, trends or prospects or future operatingor financial performance, although not all forward-looking statementscontain these identifying words.

These statements are not guarantees of performance andinvolve risks including those related to capital requirements, anduncertainties that are difficult to control or predict, and as such,they may cause future results of the Company's activity to differsignificantly from the content and implications of such statements.Forward-Looking Statements are pertinent only as of the date on whichthey are made, and the Company undertakes no obligation to update orrevise any Forward-Looking Statements to reflect new information orthe occurrence of future events or circumstances unless otherwiserequired to do so by law. Neither the Company nor its shareholders,officers, and consultants shall be liable for any action and theresults of any action taken by any person based on the informationcontained herein, including, without limitation the purchase or saleof Company securities. Nothing in this document should be deemed to bemedical or other advice of any kind. All images are for illustrativepurposes only. IzoView is not yet approved for sale.

Copyright (c) 2022 TheNewswire - All rights reserved.